BIOLIFE SOLUTIONS INC
BLFSNasdaqHealthcare · Electromedical & Electrotherapeutic Apparatus · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $96.2M | $74.6M | $68.0M | $76.2M | $119.2M | $48.1M |
| Operating income | −$16.6M | −$4.5M | −$17.2M | −$5.9M | −$35.2M | −$6.2M |
| Net income | −$4.6M | −$20.2M | −$68.0M | −$139.8M | −$8.9M | $2.0M |
| Total assets | $405.9M | $399.5M | $412.7M | $450.2M | $554.3M | $234.8M |
| Total liabilities | $34.0M | $50.6M | $75.1M | $86.0M | $76.2M | $29.6M |
| Equity | $371.9M | $348.9M | $337.7M | $364.2M | $478.0M | $204.4M |
| EPS (diluted) | $-0.10 | $-0.44 | $-1.55 | $-3.25 | $-0.23 | $-0.06 |
| Shares out. | 47.0M | 45.3M | 43.2M | 42.1M | 33.4M | 24.0M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −17.3%
- Net margin
- −4.8%
- Return on equity
- −1.2%
- Return on assets
- −1.1%
- Return on capital (ROCE)
- −4.3%
- Liabilities / assets
- 8.4%
- Debt / equity
- 0.09×
- Book value / share
- $7.91
- Revenue growth (YoY)
- 28.9%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 10.32safe
- Accruals / assets
- −6.1%clean
- Beneish M-Score
- -2.31normal
- Piotroski F-Score
- 6/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 2 warning● 5 good- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Positive operating cash flow
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗May 11, 2023
- NT 10-Kmissed a reporting deadline ↗Mar 17, 2023
- NT 10-Kmissed a reporting deadline ↗Mar 2, 2022
- NT 10-Kmissed a reporting deadline ↗Apr 30, 2020
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Casdin Capital, LlcActivist (13D)May 22, 2026
- T. Rowe Price Investment Management, Inc.Passive (13G)May 15, 2026
- Invesco Ltd.Passive (13G)May 6, 2026
- Vanguard Group IncPassive (13G)Mar 26, 2026
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Casdin Partners Master Fund, L.P.10% owner | May 19, 2026 | Sell | 300,000 | $22.65 |
| Mathew Aby J.Officer — EVP & Chief Scientific Officer | Apr 8, 2026 | Tax withholding | 515 | $19.27 |
| Berard ToddOfficer — Chief Marketing Officer | Apr 8, 2026 | Tax withholding | 293 | $19.27 |
| Wichterman TroyOfficer — Chief Financial Officer | Apr 8, 2026 | Tax withholding | 844 | $19.27 |
| Foster Karen A.Officer — Chief Quality and Operations | Mar 23, 2026 | Sell | 2,577 | $19.17 |
| De Greef RoderickOfficer — President and CEO | Mar 19, 2026 | Tax withholding | 11,101 | $19.12 |
| Berard ToddOfficer — Chief Marketing Officer | Mar 19, 2026 | Tax withholding | 1,879 | $19.12 |
| Werner SeanOfficer — Chief Technology Officer | Mar 19, 2026 | Tax withholding | 1,681 | $19.12 |
| Wichterman TroyOfficer — Chief Financial Officer | Mar 19, 2026 | Tax withholding | 3,749 | $19.12 |
| Aebersold SarahOfficer — Chief Human Resources Officer | Mar 19, 2026 | Tax withholding | 931 | $19.12 |
| Foster Karen A.Officer — Chief Quality and Operations | Mar 19, 2026 | Tax withholding | 1,907 | $19.12 |
| Mathew Aby J.Officer — EVP & Chief Scientific Officer | Mar 19, 2026 | Tax withholding | 2,255 | $19.12 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 3.8M | 10.7 | +4.1% |
| Apr 30, 2026 | 3.6M | 9.2 | +9.0% |
| Apr 15, 2026 | 3.3M | 10.5 | -7.5% |
| Mar 31, 2026 | 3.6M | 8.9 | +16.0% |
| Mar 13, 2026 | 3.1M | 4.8 | +3.5% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 7, 2026
- Regulation FD disclosureMar 2, 2026
- Results of operationsFeb 26, 2026
- Results of operationsJan 12, 2026
- Director / officer changeJan 9, 2026
- Regulation FD disclosureNov 17, 2025
- Results of operationsNov 6, 2025
- Shareholder voteAug 21, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SCHEDULE 13D/AMay 22, 2026
- 4May 21, 2026
- 144May 21, 2026
- 144May 20, 2026
- 144May 19, 2026
- SCHEDULE 13G/AMay 15, 2026
- 10-QMay 7, 2026
- 8-KMay 7, 2026
- SCHEDULE 13G/AMay 6, 2026
- 10-K/AApr 28, 2026
- 4FORM 4Apr 10, 2026
- 4FORM 4Apr 10, 2026
- 4FORM 4Apr 10, 2026
- 4FORM 4Mar 31, 2026
- SCHEDULE 13G/AMar 26, 2026